Insider Transactions in Q1 2021 at Flexion Therapeutics Inc (FLXN)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 15
2021
|
Melissa Layman Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
4,520
-4.17%
|
$49,720
$11.8 P/Share
|
|
Mar 01
2021
|
Michael D. Clayman President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
106,100
+22.15%
|
-
|
|
Mar 01
2021
|
Melissa Layman Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,100
+15.63%
|
-
|
|
Mar 01
2021
|
David Arkowitz Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
71,900
+15.02%
|
-
|
|
Mar 01
2021
|
Scott Kelley Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+17.29%
|
-
|
|
Mar 01
2021
|
Mark S. Levine General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+17.92%
|
-
|
|
Mar 01
2021
|
Christina Willwerth Chief Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+17.12%
|
-
|
|
Mar 01
2021
|
Kerry Wentworth Chief Regulatory Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+17.26%
|
-
|
|
Mar 01
2021
|
Adam Muzikant Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+22.48%
|
-
|
|
Feb 01
2021
|
Michael D. Clayman President and CEO |
SELL
Bona fide gift
|
Direct |
21,099
-5.73%
|
-
|
|
Jan 28
2021
|
Michael D. Clayman President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,776
-3.18%
|
$105,312
$12.37 P/Share
|
|
Jan 28
2021
|
Melissa Layman Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,624
-2.88%
|
$31,488
$12.55 P/Share
|
|
Jan 27
2021
|
Michael D. Clayman President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
119,500
+30.24%
|
-
|
|
Jan 27
2021
|
Melissa Layman Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+24.79%
|
-
|
|
Jan 15
2021
|
Samuel D Colella Director |
BUY
Other acquisition or disposition
|
Indirect |
671,060
+38.61%
|
-
|
|
Jan 15
2021
|
Samuel D Colella Director |
SELL
Other acquisition or disposition
|
Indirect |
3,180,675
-81.13%
|
-
|
|
Jan 08
2021
|
Michael D. Clayman President and CEO |
SELL
Bona fide gift
|
Direct |
4,762
-1.28%
|
-
|
|
Jan 05
2021
|
Michael D. Clayman President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,530
-1.59%
|
-
|
|
Jan 05
2021
|
David Arkowitz Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,073
-3.87%
|
$66,803
$11.13 P/Share
|
|
Jan 05
2021
|
Mark S. Levine General Counsel |
SELL
Open market or private sale
|
Direct |
6,829
-5.98%
|
$75,119
$11.13 P/Share
|
|
Jan 05
2021
|
Christina Willwerth Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
6,602
-5.42%
|
$72,622
$11.13 P/Share
|
|
Jan 05
2021
|
Kerry Wentworth Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
6,829
-5.66%
|
$75,119
$11.13 P/Share
|
|
Jan 05
2021
|
Scott Kelley Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,829
-5.67%
|
$75,119
$11.13 P/Share
|
|
Jan 05
2021
|
Adam Muzikant Chief Business Officer |
SELL
Open market or private sale
|
Direct |
4,005
-5.17%
|
$44,055
$11.13 P/Share
|